GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Canbridge Pharmaceuticals Inc (HKSE:01228) » Definitions » PE Ratio (TTM)

Canbridge Pharmaceuticals (HKSE:01228) PE Ratio (TTM) : At Loss (As of Mar. 17, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Canbridge Pharmaceuticals PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2025-03-17), Canbridge Pharmaceuticals's share price is HK$0.158. Canbridge Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-1.04. Therefore, Canbridge Pharmaceuticals's PE Ratio (TTM) for today is At Loss.


The historical rank and industry rank for Canbridge Pharmaceuticals's PE Ratio (TTM) or its related term are showing as below:

HKSE:01228' s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss   Med: At Loss   Max: At Loss
Current: At Loss



HKSE:01228's PE Ratio (TTM) is ranked worse than
100% of 250 companies
in the Biotechnology industry
Industry Median: 27.255 vs HKSE:01228: At Loss

Canbridge Pharmaceuticals's Earnings per Share (Diluted) for the six months ended in Jun. 2024 was HK$-0.62. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-1.04.

As of today (2025-03-17), Canbridge Pharmaceuticals's share price is HK$0.158. Canbridge Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-1.04. Therefore, Canbridge Pharmaceuticals's PE Ratio without NRI for today is At Loss.

Canbridge Pharmaceuticals's EPS without NRI for the six months ended in Jun. 2024 was HK$-0.62. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-1.04.

During the past 3 years, the average EPS without NRI Growth Rate was 25.00% per year.

During the past 5 years, Canbridge Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 25.00% per year. The lowest was -30.70% per year. And the median was -2.85% per year.

Canbridge Pharmaceuticals's EPS (Basic) for the six months ended in Jun. 2024 was HK$-0.62. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-1.04.


Canbridge Pharmaceuticals PE Ratio (TTM) Historical Data

The historical data trend for Canbridge Pharmaceuticals's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Canbridge Pharmaceuticals PE Ratio (TTM) Chart

Canbridge Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio (TTM)
N/A N/A At Loss At Loss At Loss

Canbridge Pharmaceuticals Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of Canbridge Pharmaceuticals's PE Ratio (TTM)

For the Biotechnology subindustry, Canbridge Pharmaceuticals's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Canbridge Pharmaceuticals's PE Ratio (TTM) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Canbridge Pharmaceuticals's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Canbridge Pharmaceuticals's PE Ratio (TTM) falls into.



Canbridge Pharmaceuticals PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Canbridge Pharmaceuticals's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=0.158/-1.040
=At Loss

Canbridge Pharmaceuticals's Share Price of today is HK$0.158.
For company reported semi-annually, Canbridge Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-1.04.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Canbridge Pharmaceuticals  (HKSE:01228) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Canbridge Pharmaceuticals PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of Canbridge Pharmaceuticals's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Canbridge Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
Building 21, No. 388 Xinping Street, Unit 18, 6th Floor, Suzhou Industrial Park, Suzhou, CHN
Canbridge Pharmaceuticals Inc is a biopharmaceutical company. It is committed to the research, development, and commercialization of biotech therapies targeting rare diseases and rare oncology. The company's core product in the rare oncology area CAN008, is a glycosylated CD95-Fc fusion protein being developed for the treatment of glioblastoma multiforme (GBM). In the rare disease area, the company have seven biologics and small molecules products and product candidates for the treatment of Hunter Syndrome (MPS II) and other lysosomal storage disorders (LSDs), complement mediated disorders, hemophilia A, metabolic disorders, and rare cholestatic liver diseases including ALGS, PFIC and BA. Its pipeline consists of biologics, small molecules, and gene therapy solutions and 13 drugs.
Executives
Xue James Qun 2101 Beneficial owner
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Athos Capital Limited 2102 Investment manager
Moskey Matthew Love 2201 Interest of corporation controlled by you
Schulte-hillen Friedrich Bela 2201 Interest of corporation controlled by you
Athos Asia Event Driven Master Fund 2101 Beneficial owner
Ctx Pharma Holdings Limited 2101 Beneficial owner
Kolchinsky Anna Inge Leonore Haas 2202 Interest of your spouse
Kolchinsky Peter 2305 Beneficiary of a trust
Ra Capital Management, L.p. 2102 Investment manager
Ra Capital Healthcare Fund Gp, Llc 2201 Interest of corporation controlled by you
Ra Capital Healthcare Fund, L.p. 2101 Beneficial owner
Wuxi Apptec Co., Ltd.
Qiming Corporate Gp Iv, Ltd. 2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p. 2201 Interest of corporation controlled by you

Canbridge Pharmaceuticals Headlines

No Headlines